Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.60 |
| ▸ | ERBB3 | P21860 | 13/20 | 0.60 |
| ▸ | ERBB4 | Q15303 | 13/20 | 0.60 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.59 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.59 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | PIM1 | P11309 | 1/20 | 0.56 |
| ▸ | PRKACA | P17612 | 1/20 | 0.56 |
| ▸ | LTK | P29376 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.56 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.56 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.56 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.56 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.56 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.56 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16432121 | 0.87 | EGFR (0.71) | EGFRERBB2ERBB3ERBB4TTBK1 | |
| SCHEMBL4740956 | 0.82 | EGFR (0.68) | EGFRERBB2ERBB3ERBB4TTBK1 | |
| SCHEMBL2747938 | 0.81 | TOP2A (0.67) | EGFRERBB2ERBB3ERBB4KDM4E | |
| SCHEMBL4544688 | 0.80 | TTBK1 (0.64) | EGFRERBB2ERBB3ERBB4TTBK1 | |
| SCHEMBL28541250 | 0.78 | TTBK1 (0.54) | EGFRERBB2TTBK1TTBK2DAPK3 | |
| SCHEMBL4544686 | 0.76 | LMNA (0.61) | EGFRKDM4EMAPK1HTT | |
| SCHEMBL2748537 | 0.75 | EGFR (0.80) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL18963653 | 0.75 | DYRK1A (0.53) | EGFRERBB2ERBB3ERBB4DYRK1A | |
| SCHEMBL168084 | 0.75 | TTBK1 (1.00) | EGFRTTBK1TTBK2AURKB | |
| SCHEMBL2749045 | 0.74 | EGFR (0.72) | EGFRERBB2ERBB3ERBB4TTBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1752457-B1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-03-19 | — | — | EP | disclosed |
| US-8178543-B2 | growth factor receptor tyrosine kinase inhibitor; anticarcinogenic agents; N-{2-[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}-3-hydroxy-3-methylbutanamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178543-B2 | growth factor receptor tyrosine kinase inhibitor; anticarcinogenic agents; N-{2-[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}-3-hydroxy-3-methylbutanamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| EP-2359825-A2 | Combination drug | Takeda Pharmaceutical Company Limited (JP) | 2011-08-24 | — | — | EP | disclosed |
| WO-2011040212-A1 | THERAPEUTIC AGENT FOR BRAIN TUMOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-07 | — | — | WO | disclosed |
| US-20110003805-A1 | CONCOMITANT DRUG | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2255830-A1 | CONCOMITANT DRUG | Takeda Pharmaceutical Company Limited (JP) | 2010-12-01 | — | — | EP | disclosed |
| EP-2253633-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| US-7825127-B2 | Method for treating cancer | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2010-11-02 | — | — | US | disclosed |
| US-7825127-B2 | Method for treating cancer | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2010-11-02 | — | — | US | disclosed |
| US-20090018335-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20080214584-A1 | Method for treating cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-04 | — | — | US | disclosed |
| US-20080214584-A1 | Method for treating cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-04 | — | — | US | disclosed |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | LEXICON PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | LEXICON PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008044782-A2 | COMBINATION DRUG | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-04-17 | — | — | WO | disclosed |
| US-20070244132-A1 | Fused Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070244132-A1 | Fused Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-18 | — | — | US | disclosed |
| WO-2007064045-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-07 | — | — | WO | disclosed |
| EP-1752457-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244132-A1 | Fused Heterocyclic Compound | NOX3, ERBB3, CBR3 | EGFR 68/4885ERBB2 21/4885ERBB3 2/4885 |
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | TNF, IL6, CXCL8 | EGFR 1259/4885ERBB2 2032/4885ERBB3 3193/4885 |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | CPT1B, CPT1A, SHBG | EGFR 3860/4885ERBB2 3708/4885ERBB3 2950/4885 |
| US-20080214584-A1 | Method for treating cancer | ERBB2, EGFR, ERBB3 | EGFR 2/4885ERBB2 1/4885ERBB3 3/4885 |
| US-20090018335-A1 | FUSED HETEROCYCLIC COMPOUND | NOX3, ERBB3, CBR3 | EGFR 68/4885ERBB2 21/4885ERBB3 2/4885 |
| US-20110003805-A1 | CONCOMITANT DRUG | ERBB2, MTOR, ERBB4 | EGFR 6/4885ERBB2 1/4885ERBB3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.